Skip to main content
SynAct Pharma logo

SynAct Pharma — Investor Relations & Filings

Ticker · SYNACT ISIN · SE0008241491 LEI · 549300RRYIEFEQ72N546 ST Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2024-08-20 Interim / Quarterly Rep…
Country SE Sweden
Listing ST SYNACT

About SynAct Pharma

https://synactpharma.com/en/

SynAct Pharma is a clinical-stage biotechnology company developing innovative medicines designed to resolve inflammation rather than solely inhibit it. The company's approach focuses on resolution therapy by leveraging melanocortin biology to restore immune balance. Its lead candidate, Resomelagon (AP1189), is a once-daily oral therapy that selectively activates melanocortin receptors on key immune cells. SynAct Pharma's development programs target a broad range of inflammatory conditions, including early intervention in chronic diseases to limit progression and the modulation of hyperinflammatory stages in acute viral diseases to reduce the risk of severe organ dysfunction.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for SynAct Pharma AB covering the period January to June 2024. It contains comprehensive financial statements, including the income statement, balance sheet, cash flow analysis, and notes, as well as management commentary and operational updates. It is clearly a formal interim financial report, not an announcement or a summary. H1 2024
2024-08-20 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report for the second quarter 2024 and first six months' and contains comprehensive financial statements, including income statements, balance sheets, cash flow reports, and management commentary for the specified period. It is a formal quarterly financial report, not an announcement or a summary, and thus fits the definition of an Interim/Quarterly Report (IR). Q2 2024
2024-08-20 English
Bulletin from the annual general meeting 2024 in SynAct Pharma AB
AGM Information Classification · 99% confidence The document is explicitly titled "Bulletin from the annual general meeting 2024 in SynAct Pharma AB" and details the resolutions passed during this meeting, such as the adoption of accounts, election of the Board, remuneration, and approval of share option programs. This content directly corresponds to the materials presented or summarized from an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information). The document is a summary/bulletin, not a proxy statement (PSI) or a formal voting result declaration (DVA), but rather the official record of what transpired at the AGM.
2024-05-31 English
Kommuniké från årsstämma 2024 i SynAct Pharma AB
AGM Information Classification · 100% confidence The document is explicitly titled "Kommuniké från årsstämma 2024 i SynAct Pharma AB" (Communiqué from the Annual General Meeting 2024 in SynAct Pharma AB). It details the key resolutions passed at the meeting, such as the approval of accounts, discharge of directors, election of the board, approval of remuneration, changes to the articles of association, and authorization for new share issues/option programs. This content directly corresponds to the materials and outcomes of an Annual General Meeting. Therefore, the appropriate classification is AGM-R (AGM Information).
2024-05-31 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for SynAct Pharma AB covering the period January to March 2024. It contains comprehensive financial statements (income statement, balance sheet, cash flow), management commentary, and operational updates. It is not an announcement of a report, but the report itself, and it contains substantive financial data, fitting the definition of an Interim/Quarterly Report (IR). Q1 2024
2024-05-31 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report for the first quarter 2024' and contains comprehensive financial statements (Income statement, Report on financial position, Cash flow), management commentary, and operational updates for the period ending March 31, 2024. It meets the criteria for an Interim/Quarterly Report as it provides substantive financial data and analysis for a period shorter than a full fiscal year. Q1 2024
2024-05-31 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.